Skip to content

Clinical study on Alkaline Water in healthy subjects

A Randomized, Controlled, Double Blind clinical study to evaluate use of Hydron Alkaline Ionized Water (HAIW) in healthy participants - NIL

Status
Active, not recruiting
Phases
Phase 1Phase 2
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2024/06/068585
Enrollment
24
Registered
2024-06-07
Start date
Unknown
Completion date
Unknown
Last updated
2024-10-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Intervention1: Hydron Alkaline Ionized Water (HAIW): Dosage and Treatment Duration: Subjects will be asked to drink at least 3 Liters of HAIW apart from the water used for food for 7 days Control In

Sponsors

Hydron Alkaline Aqua Pvt. Ltd.
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Healthy Male and Female participants in the age group of 21-40 Years 2. Subjects of female gender or non-pregnant, non-lactating females. A urine pregnancy test is required for all female subjects of childbearing potential unless female subject has had a hysterectomy, tubal ligation, or is greater than 2 years postmenopausal. 3. Subjects willing to follow the procedures as per the study protocol and voluntarily sign an informed consent form.

Exclusion criteria

Exclusion criteria: 1. Known cases of any Severe and Chronic disease. 2. Known subject of any active malignancy. 3. Subjects giving history of significant cardiovascular event less than 12 weeks prior to randomization. 4. Subjects having known chronic, contagious infectious disease, such as active tuberculosis, Hepatitis B or C, or HIV. 5. Known subjects of having active metabolic or gastrointestinal diseases that may interfere with nutrient absorption, metabolism, or excretion, excluding diabetes. 6. Subjects with Diabetes and Hypertension 7. Subjects using any other investigational drug within 1 month prior to recruitment. 8. Known hypersensitivity to alkaline water 9. Pregnant and Lactating females. 10. Subjects currently participating in any other Clinical study. 11. Any other condition due to which patients are deemed to be unsuitable by the investigator for reason(s) not specifically started in the exclusion criteria.

Design outcomes

Primary

MeasureTime frame
1.Safety related lab parameters including CBC, LFT, RFT, Blood Sugar, ECG, Sr. Electrolytes 2.Safety by evaluation of adverse events based on clinical signs and symptoms Timepoint: Screening visit (Day -3), Baseline visit (Day 0), Every day till next 7 days

Secondary

MeasureTime frame
1. Changes in digestion related symptoms (appetite, digestion, bowel habits) 2. Change in urine output and symptoms 3. Change in sleep quality 4. Change in overall quality of life 5. Change in level of Energy, level of stamina and physical strength 6. Change in daytime fatigue using Fatigue Severity Scale (FSS) 7. Change in Global evaluation for overall change on CGI-I Scale by physician and subjects 8. Change in global assessment of overall safety by physician and subjectsTimepoint: Screening visit (Day -3), Baseline visit (Day 0), Every day till next 7 days

Countries

India

Contacts

Public ContactDr Sanjay Tamoli

Target Institute of Medical Education and Research Pvt. Ltd

targetinstitute@yahoo.com09322522252

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026